AngioDynamics

AngioDynamics Equity

The The Equity of AngioDynamics (ANGO) as of Sep 20, 2026 is 170.83 M USD. In the previous year, The Equity was 182.97 M USD — a change of -6.64% (lower).

Equity

170.83 MUSD

YoY

-6.64%

Last updated:

In 2026, AngioDynamics's equity was 170.83 M USD, a -6.64% increase from the 182.97 M USD equity in the previous year.

The AngioDynamics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
614.82 M USD
Jan 1, 2020
455.87 M USD
Jan 1, 2021
439.46 M USD
Jan 1, 2022
424.49 M USD
Jan 1, 2023
378.30 M USD
Jan 1, 2024
205.59 M USD
Jan 1, 2025
182.97 M USD
Jan 1, 2026
170.83 M USD
The AngioDynamics Equity history
YEAREquityYoY
170.83 MUSD-6.64%
182.97 MUSD-11.00%
205.59 MUSD-45.65%
378.30 MUSD-10.88%
424.49 MUSD-3.41%
439.46 MUSD-3.60%
455.87 MUSD-25.85%
614.82 MUSD+13.31%
542.60 MUSD+4.95%
517.03 MUSD+1.97%
507.03 MUSD-6.97%
545.02 MUSD+1.33%
537.89 MUSD
Access this data via the Eulerpool API

AngioDynamics Stock analysis

What does AngioDynamics do? AngioDynamics Inc is a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company was founded in 1988 and is headquartered in Latham, New York. Over the years, AngioDynamics has evolved into a conglomerate through several acquisitions and partnerships, specializing in various areas. The key divisions include Vascular Access Solutions, Oncology Solutions, and Peripheral Vascular Solutions. AngioDynamics focuses on developing and manufacturing innovative technologies that improve medical care and promote patient health. The company develops and distributes a wide range of medical devices and procedures to treat diseases such as cancer, venous diseases, and thrombosis. In the Vascular Access Solutions division, AngioDynamics offers a wide range of devices for establishing vascular access, which are necessary for the treatment of serious illnesses. This includes port systems and catheters that facilitate access to the body's vascular system. AngioDynamics' Oncology Solutions provide targeted cancer treatment options, including ultrasound-controlled radiofrequency ablation systems and fusion biopsy systems. The development of innovative diagnostic and treatment options is a focus of AngioDynamics. A majority of AngioDynamics' products are in the Peripheral Vascular Solutions division. Here, the company develops devices and procedures for the treatment of peripheral vascular diseases such as varicose veins or chronic venous insufficiency. This includes procedures like laser and radiofrequency treatments that can be performed minimally invasively. AngioDynamics has gained an excellent reputation in the medical industry due to its high-quality products, innovative technologies, and close collaboration with medical professionals. The company places great emphasis on providing optimal care to every patient and therefore serves hospitals, clinics, and medical practices worldwide. Over the years, AngioDynamics has become a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company has built a broad customer base worldwide and has become an important player in the medical industry due to the quality and innovation of its products. AngioDynamics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing AngioDynamics's Equity

AngioDynamics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding AngioDynamics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating AngioDynamics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

AngioDynamics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in AngioDynamics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about AngioDynamics stock

The Equity of AngioDynamics is 170.83 M USD in 2026.

The Equity of AngioDynamics changed from 182.97 M USD to 170.83 M USD, representing a -6.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity AngioDynamics since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's AngioDynamics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — AngioDynamics

All Key Metrics — AngioDynamics